Information  X 
Enter a valid email address

GlaxoSmithKline PLC (GSK)

  Print      Mail a friend       Annual reports

Wednesday 19 April, 2017

GlaxoSmithKline PLC

Director/PDMR Shareholding

RNS Number : 7706C
GlaxoSmithKline PLC
19 April 2017
 

GlaxoSmithKline plc (the 'Company')

 

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.47

82.730 (personal contribution)

£16.47

204.873 (personal contribution)

£16.47

223.059 (personal contribution)

£16.47

82.730 (personal contribution)

£16.47

204.858 (personal contribution)

£16.47

223.045 (personal contribution)

£16.47

82.730 (matching shares)

£16.47

204.873 (matching shares)

£16.47

223.059 (matching shares)

£16.47

82.730 (matching shares)

£16.47

204.858 (matching shares)

£16.47

223.045 (matching shares)

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

2,042.590

£16.47

 

 

 

e)

Date of the transaction

2017-04-18

f)

Place of the transaction

 

n/a

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Manufacturing & Supply

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.47

60.585 (personal contribution)

£16.47

139.194 (personal contribution)

£16.47

116.145 (personal contribution)

£16.47

60.585 (personal contribution)

£16.47

116.131 (personal contribution)

£16.47

60.585 (matching shares)

£16.47

139.194 (matching shares)

£16.47

116.145 (matching shares)

£16.47

60.585 (matching shares)

£16.47

116.131 (personal contribution)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

985.280

£16.47

 

 

 

e)

Date of the transaction

2017-04-18

f)

Place of the transaction

 

n/a

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Debruyne

b)

Position/status

President, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.47

195.213 (personal contribution)

£16.47

195.199 (personal contribution)

£16.47

195.213 (matching shares)

£16.47

195.199 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

780.824

£16.47

 

 

 

e)

Date of the transaction

2017-04-18

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.47

115.556 (personal contribution)

£16.47

270.551 (personal contribution)

£16.47

202.642 personal contribution)

£16.47

115.540 (personal contribution)

£16.47

270.537 (personal contribution)

£16.47

202.642 (personal contribution)

£16.47

115.556 (matching shares)

£16.47

270.551 (matching shares)

£16.47

202.642 (matching shares)

£16.47

115.540 (matching shares)

£16.47

270.537 (matching shares)

£16.47

202.642 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

2,354.936

£16.47

 

 

 

e)

Date of the transaction

2017-04-18

f)

Place of the transaction

 

n/a

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.47

42.420 (personal contribution)

£16.47

100.034 (personal contribution)

£16.47

73.412 (personal contribution)

£16.47

42.420 (personal contribution)

£16.47

100.034 (personal contribution)

£16.47

73.398 (personal contribution)

£16.47

42.420 (matching shares)

£16.47

100.034 (matching shares)

£16.47

73.412 (matching shares)

£16.47

42.420 (matching shares)

£16.47

100.034 (matching shares)

£16.47

73.398 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

863.436

£16.47

 

 

 

e)

Date of the transaction

2017-04-18

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S A Hussain

b)

Position/status

President, Global Pharmaceuticals

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.47

199.970 (personal contribution)

£16.47

236.389 (personal contribution)

£16.47

202.908 personal contribution)

£16.47

236.389 (personal contribution)

£16.47

202.894 (personal contribution)

£16.47

199.970 (matching shares)

£16.47

236.389 (matching shares)

£16.47

202.908 (matching shares)

£16.47

236.389 (matching shares)

£16.47

202.894 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

2,157.100

£16.47

 

 

 

 

e)

Date of the transaction

2017-04-18

f)

Place of the transaction

 

n/a

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr B McNamara

b)

Position/status

CEO, GSK Consumer Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W1053 

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 April 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$41.81

82.979 (personal contribution)

$41.81

82.979 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

165.958

$41.81

 

 

 

 

e)

Date of the transaction

2017-04-18

f)

Place of the transaction

 

n/a

 

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.47

67.977 (personal contribution)

£16.47

127.311 (personal contribution)

£16.47

92.391 (personal contribution)

£16.47

67.977 (personal contribution)

£16.47

127.311 (personal contribution)

£16.47

92.377 (personal contribution)

£16.47

67.977 (matching shares)

£16.47

127.311 (matching shares)

£16.47

92.391 (matching shares)

£16.47

67.977 (matching shares)

£16.47

127.311 (matching shares)

£16.47

92.377 (matching shares)

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

1,150.688

£16.47

 

 

 

e)

Date of the transaction

2017-04-18

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.47

91.499 (personal contribution)

£16.47

186.252 (personal contribution)

£16.47

139.061(personal contribution)

£16.47

91.483 (personal contribution)

£16.47

186.252 (personal contribution)

£16.47

139.061 (personal contribution)

£16.47

91.499 (matching shares)

£16.47

186.252 (matching shares)

£16.47

139.061 (matching shares)

£16.47

91.483 (matching shares)

£16.47

186.252 (matching shares)

£16.47

139.061 (matching shares)

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

1,667.216

£16.47

 

 

 

e)

Date of the transaction

2017-04-18

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.47

62.146 (personal contribution)

£16.47

113.955 (personal contribution)

£16.47

87.545 (personal contribution)

£16.47

62.146 (matching shares)

£16.47

113.955 (matching shares)

£16.47

87.545 matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

527.292

£16.47

 

 

 

e)

Date of the transaction

2017-04-18

f)

Place of the transaction

 

n/a

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D E Troy

b)

Position/status

SVP & General Counsel

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W1053

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 April 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$41.81

47.220 (personal contribution)

$41.81

106.319 (personal contribution)

$41.81

88.057 (personal contribution)

$41.81

47.220 (personal contribution)

$41.81

106.319 (personal contribution)

$41.81

88.044 (personal contribution)

$41.81

47.220 (matching shares)

$41.81

106.319  (matching shares)

$41.81

88.057  (matching shares)

$41.81

47.220  (matching shares)

$41.81

106.319  (matching shares)

$41.81

88.044 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

966.358

$41.81

 

e)

Date of the transaction

2017-04-18

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr P J T Vallance

b)

Position/status

President, R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.47

134.685 (personal contribution)

£16.47

219.092 (personal contribution)

£16.47

151.043 (personal contribution)

£16.47

134.685 (personal contribution)

£16.47

219.092 (personal contribution)

£16.47

151.043 (personal contribution)

£16.47

134.685 (matching shares)

£16.47

219.092 (matching shares)

£16.47

151.043 (matching shares)

£16.47

134.685 (matching shares)

£16.47

219.092 (matching shares)

£16.47

151.043 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

2,019.280

£16.47

 

 

 

e)

Date of the transaction

2017-04-18

f)

Place of the transaction

 

n/a

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHEKLFFDZFBBBF

a d v e r t i s e m e n t